Preclinical Amyloid-beta and Axonal Degeneration Pathology in Delirium by Idland, A-V et al.
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium 
 
Idland A-V; Wyller TB; Stoen R; Eri LM; Frihagen F; Raeder J; Chaudhry FA; Hansson O; 
Zetterberg H; Blennow K; Bogdanovic N, Brækhus A, Watne LO. 
1Oslo Delirium Research Group, Department of Geriatric Medicine, University of Oslo, Oslo, 
Norway 
2Institute of Clinical Medicine, University of Oslo, Oslo, Norway 
3Research Group for Lifespan Changes in Brain and Cognition, Department of Psychology, 
University of Oslo, Oslo, Norway 
4Department of Anesthesiology, Oslo University Hospital, Oslo, Norway 
5Department of Urology, Oslo University Hospital, Oslo, Norway 
6Department of Orthopedic Surgery, Oslo University Hospital, Oslo, Norway 
7Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway 
8Department of Clinical Sciences, Lund University, Lund, Sweden 
9Memory Clinic, Skåne University Hospital, Lund, Sweden 
10Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Department of 
Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, 
Gothenburg, Sweden 
11Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK 
12Memory Clinic, Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway 
13Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, 
Tønsberg 
14Department of Neurology, Oslo University Hospital, Oslo, Norway 
 
Correspondence: Ane-Victoria Idland, Oslo University Hospital, Ullevål, Department of 
Geriatric Medicine, PB 4956 Nydalen, 0424 Oslo, Norway. Telephone: + 47 – 91881081, E-
mail: av.idland@gmail.com. 
 
Authors’ contributions: 
Study concept and design: Idland, Ræder, Hansson, Brækhus, Wyller, Watne. 
Acquisition of clinical data: Idland, Støen, Eri, Frihagen, Brækhus, Wyller, Watne. 
Analysis of CSF: Zetterberg, Blennow. 
Data analysis: Idland, Bogdanovic,Wyller, Watne. 
Interpretation of data: Idland, Støen, Eri, Frihagen, Ræder, Chaudhry, Hansson, Zetterberg, 
Blennow, Bogdanovic, Brækhus, Wyller, Watne. 
Drafting of the manuscript: Idland, Wyller, Watne. 
Critical revision of the manuscript for important intellectual content: Idland, Støen, Eri, 
Frihagen, Ræder, Chaudhry, Hansson, Zetterberg, Blennow, Bogdanovic, Brækhus, Wyller, 
Watne. 
Statistical analysis: Idland, Watne. 
Obtained funding: Wyller. 
Administrative, technical or material support:  Idland, Støen, Eri, Frihagen, Brækhus, Wyller, 
Watne. 
 
Conflicts of interest: Dr. Watne has given a lecture on delirium for Lilly. Dr. Blennow has 
served on Advisory Boards for IBL International and Roche Diagnostics. Prof. Wyller has 
given lectures on delirium for Pfizer, Roche, AstraZeneca and Nycomed. No other 
disclosures reported. 
 
Word count: 2991 
 
 
 
 
 
 
ABSTRACT  
Importance: A large proportion of cognitively normal elderly have biomarker evidence of 
brain β-amyloidosis, but it is not settled whether this represents preclinical Alzheimer’s 
disease (AD) or have any clinical consequences. Delirium and dementia are closely 
interrelated, and common pathophysiological mechanisms are believed to exist. Clinical 
studies on elderly developing delirium may thus give pathophysiological clues. 
Objective: To determine whether the AD cerebrospinal fluid (CSF) biomarkers Aβ42, total 
tau (T-tau) and phosphorylated tau (P-tau) can indicate an increased risk of delirium in hip 
fracture patients with and without dementia. 
Design: Prospective cohort study carried out from September 2009 to January 2012. 
Setting: University-affiliated hospitals in Oslo, Norway.  
Participants: A consecutive cohort (n=143) of participants in the Oslo Orthogeriatric Trial 
(n=332) with CSF samples collected in conjunction to spinal anesthesia (n=143).  
Main Outcome and Measures: Delirium was assessed using the Confusion Assessment 
Method (CAM) once daily in all hip fracture patients, preoperatively and until the fifth 
postoperative day (until discharge for delirious patients). The diagnosis of dementia at 
admission was based upon clinical consensus. CSF levels of Aβ42, Aβ40, T-tau, and P-tau 
were analyzed.  
Results: Preoperative CSF samples from 70 hip fracture patients with and 59 without 
delirium were analyzed. Markedly CSF Aβ1-42 levels (median [range], 267 [125 to 713] 
ng/L vs 461 [125 to 1086] ng/L, p<.001), mildly increased T-tau levels (median [range], 439 
[91 to 1380] ng/L vs 360 [133 to 1034] ng/L, p=.006), but no change in P-tau were found in 
hip fracture patients who developed delirium compared to those who remained lucid. In 
analyses stratified on dementia status, differences were only statistically significant in the 
dementia-free stratum, and they remained so after adjusting for cognitive impairment in 
logistic regression analyses.  
Conclusions and Relevance: The marked reduction in CSF Aβ42 and mild increase in T-tau 
in cognitively normal elderly hip fracture patients developing delirium suggest that 
preclinical brain amyloidosis is clinically relevant. These biomarkers may also possibly be 
used clinically to identify patients at risk of developing delirium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The application of biomarkers for Alzheimer’s disease (AD) pathogenic processes have 
allowed clinical studies exploring at what time-point during the course of the disease β-
amyloidosis, tau pathology and neurodegeration occur, for review see (ref 11 – Jack 2013). It 
is recognized that a large proportion (up to 28% at age 75) of cognitively normal elderly have 
brain β-amyloidosis (Jack Jr CR, Lancet Neurol 2014;13:997–1005), but it is not settled 
whether this represents preclinical AD or have any clinical consequences. 
Delirium represents an acute and fluctuating reduction in attention, awareness and cognition, 
commonly precipitated by an acute somatic condition. Dementia represents decline in 
memory and at least one other cognitive domain which interferes with independence in 
everyday activities.1 AD accounts for around 60 % of all dementia cases.2  Cognitive 
impairment and dementia are strong risk factors for delirium,3 and delirium is independently 
associated with an increased incidence of chronic cognitive decline and dementia.3 Thus, 
delirium and dementia are closely interrelated, and common pathophysiological mechanisms 
are believed to exist.3,4 The pathophysiological links are, however, not known.3 
Aβ42, total tau (T-tau) and phosphorylated tau (P-tau) are the core AD cerebrospinal fluid 
(CSF) biomarkers AD, and are believed to reflect brain pathophysiology. Reduced CSF Aβ42 
concentration reflects accumulation of aggregated Aβ in amyloid plaques.5,6 Increased T-tau 
level reflects the intensity of axonal degeneration,7,8 while increased P-tau level correlates 
with the amount of tangle pathology in the brain.9 Aβ42 decreases at least 5-10 years before 
progression to AD dementia, while P-tau and T-tau are later markers.10,11 This implies that 
cognitively normal elderly and mild cognitive impairment (MCI) patients may have 
neuropathological features of AD in their brains.  
Because delirium and dementia are clinically and epidemiologically interrelated, these CSF 
biomarkers may predict the occurrence of delirium, but studies so far show conflicting 
results. 13.14  
The aim of our study was to examine if the AD the CSF biomarkers can indicate an increased 
risk of delirium in hip fracture patients with and without dementia. 
 
METHODS 
 
Participants 
 
Patients were recruited from The Oslo Orthogeriatric Trial (OOT): a randomized, controlled, 
trial comparing orthogeriatric care with usual orthopedic care. Delirium incidence was a 
secondary outcome, and there was no difference in delirium rates between intervention and 
control group. A predefined secondary aim was to collect CSF in conjunction with spinal 
anesthesia in order to elucidate pathophysiological mechanisms in delirium. The OOT 
assessed for eligibility all patients that were acutely admitted to the Ullevaal Clinic of Oslo 
University Hospital with a hip fracture from September 2009 to January 2012. Patients were 
excluded if regarded as moribund and if the hip fracture was part of a high energy trauma. 
Details have been published previously.15,16 
 
A reference group was recruited from February 2012 to June 2013. Aged 65 years or older, 
they were undergoing elective surgery in spinal anesthesia. Exclusion criteria were dementia, 
Parkinson’s disease, previous stroke, or other central nervous system (CNS) disorders likely 
to affect cognition. The participants underwent cognitive testing before surgery, and CSF 
samples were collected in conjunction to spinal anesthesia.  
 
Assessments  
 
Relatives or health professionals were interviewed regarding pre-fracture status. Pre-fracture 
cognitive status was assessed using the Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE)17 and pre-fracture Activities of Daily Living (ADL) performance was 
assessed by the Barthel Index.18 Acute Physiology and Chronic Health Evaluation 
(APACHE) II score19 at admittance and the American Society of Anesthesiologists (ASA) 
score20 before hip fracture surgery were also recorded. Delirium was assessed once daily by 
the study geriatrician (LOW) or a study nurse using the Confusion Assessment Method 
(CAM),21 both preoperatively and postoperatively. All patients were screened until the fifth 
postoperative day, and delirious patients were screened until discharge. CAM scores were 
based on an interview with the patient, including tests of cognition, attention and alertness 
(digit span test, orientation and delayed recall), information from close relatives and nurses, 
and review of hospital records from the previous 24 hours. The diagnosis of dementia at 
admission was based upon consensus between an experienced old age psychiatrist (KE) and 
an experienced geriatrician (TBW) who independently assessed whether the hip fracture 
patients fulfilled the ICD-10 criteria1 for dementia. They were allowed access to relevant 
information extracted from clinical records, e.g. previous dementia diagnoses and cognitive 
test results, as well as scores on IQCODE, Clinical Dementia Rating (CDR),22 and 
Nottingham Extended ADL Scale (NEADL)23 at admission and cognitive test results, CDR 
score, and NEADL score at one-year follow-up. They were blind to records of delirium status 
during the hospital stay. Inter-rater agreement was very good (kappa 0.87), and 
disagreements were resolved through discussion. 
 
The cognitive assessment prior to surgery in the reference group included the Clock Drawing 
Test,24 Word List Memory Task from the Consortium to Establish a Registry for Alzheimer´s 
Disease battery,25 Trail Making Test A and B,26 Kendrick Object Learning Test,27 Controlled 
Oral Word Association Test (FAS version),28-30 and Animal Naming.30,31 A relative or friend 
filled in the IQCODE. Only cognitively normal older individuals, defined as maximum one 
abnormal score on the tests, were included in the reference group. A score < 4/5 on the Clock 
Drawing Test, and scores more than 2 standard deviations below the mean for age, gender 
and educational level for all other tests, were considered abnormal.  
 
Cerebrospinal Fluid Collection, Selection and Analyses  
 
CSF samples were obtained from 143 of 332 patients included in OOT. 14 patients were later 
excluded (eFigure 1). Demographics, delirium incidence, IQCODE scores, and proportion 
with dementia were not statistically significantly different in the 129 patients left for present 
analyses compared with the remaining OOT patients. CSF was obtained from 155 of the 172 
subjects in the reference group, and after exclusion of cognitively abnormal subjects, 121 
cognitively normal older individuals remained for present analyses (eFigure 1).  
 
CSF was collected in polypropylene tubes, centrifuged, the supernatant aliquoted in 
polypropylene vials, frozen as soon as possible, and stored at -80°C pending analyses. CSF 
from hip fracture patients was thawed, aliquoted once more in polypropylene vials and frozen 
again before analyses.  
 
In December 2013, the frozen supernatant samples of CSF were sent on dry ice to the 
Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital, Mölndal, Sweden, 
for analyses. Aβ1-42, T-tau and P-tau concentrations were determined using INNOTEST 
enzyme-linked immunosorbent assays (Fujirebio, Ghent, Belgium). The INNOTEST Aβ42 
method employs antibodies that specifically detect the neo-epitopes of the first and last amino 
acid of the 42 amino acid-long Aβ sequence.32 INNOTEST Aβ42 will hereafter be designated 
Aβ1-42. Aβ42 concentrations were also measured using the Meso Scale Discovery (MSD) 
Aβ Triplex Assay (Meso Scale Discovery, Rockville, Maryland). This assay uses end-
specific antibodies to capture Aβ peptides ending at amino acid 38, 40 and 42, respectively, 
and 6E10 (specific to amino acids 3 to 8) to detect them. MSD Aβ will hereafter be 
designated AβX-38, AβX-40 and AβX-42. Values outside the quantification limits were 
imputed as the quantification limit, 125 ng/L for Aβ1-42 (4 patients) and 1380 ng/L for T-tau 
(3 patients). All analyses were performed by board-certified laboratory technicians, who were 
masked to clinical data, using one batch of reagents with intra-assay coefficients of variation 
below 10%.  
 
Statistical analyses 
 
Due to a non-normal distribution of the data, Mann-Whitney U-tests were used for analyses 
of continuous variables. Chi-Square or Fisher’s Exact Tests were used for analyses of 
categorical variables. We calculated ratios of Aβ1-42 to T-tau and P-tau because they may 
increase the predictive value of the CSF biomarkers.33 Aβ40 is thought to reflect the total Aβ 
peptide production;34,35 we therefore calculated a ratio of AβX-42 to AβX-40 to account for 
inter-individual differences in Aβ42 levels. ELISA concentrations for Aβ42 were used, 
except in the Aβ42 to Aβ40 ratio where we used the Triplex concentration. Subjects were 
classified as Aβ1-42+ (< 530 ng/L) or Aβ1-42- (≥ 530 ng/L), T-tau+ (> 350 ng/L) or T-tau- 
(≤ 350 ng/L), and P-tau+ (≥ 60 ng/L) or P-tau- (< 60 ng/L) according to cut-off values 
suggested by Hansson et al.36 Logistic regression analyses were conducted to adjust for 
potential confounding of the association between biomarker concentrations and delirium.  
 
Ethical considerations  
 
The studies were conducted in accordance with the Declaration of Helsinki. Informed consent 
was obtained from the patients. If a hip fracture patient was unable to give an informed 
consent, a presumed consent in combination with assent from the closest relative was 
obtained. Sampling of both cohorts was approved by the Regional Committee for Ethics in 
Medical Research in Norway (REK S-09169a and REK 2011/2052).  
 
RESULTS 
 
Delirium versus no delirium 
 
Demographics of the included patients and the reference group are given in Table 1. Seventy 
(54%) of the patients with available CSF developed delirium in conjunction to the hip 
fracture, either preoperatively or postoperatively (Table 1). These patients were older, had 
higher morbidity, and were more dependent in ADL. They also showed a greater prevalence 
of dementia and nursing home residency, compared with the hip fracture patients who did not 
develop delirium. CSF Aβ1-42 levels were markedly lower (36% of control levels) in 
patients who developed delirium, and 91% of patients with delirium were Aβ1-42+ (Table 1). 
CSF T-tau levels were slightly higher in patients with delirium (126% of control levels), and 
the proportion of patients being T-tau+ did not significantly differ from those without 
delirium (Table 1). CSF P-tau levels and proportion of P-tau+ patients did not differ between 
patients who did and did not develop delirium. CSF AβX-42, AβX-40, and AβX-38 
concentrations were significantly lower in hip fracture patients with delirium than in those 
without (Table 1).  
 
Preoperative delirium versus postoperative delirium 
 
Forty-three of the patients with delirium developed delirium preoperatively, while 22 patients 
developed delirium postoperatively (preoperative delirium status missing in five patients). 
The CSF biomarker levels were not significantly different between patients who developed 
delirium before or after surgery (data not shown).   
 
Dementia versus no dementia 
 
Fifty-four/sixty-four (84 %) demented hip fracture patients developed delirium compared 
with 16/65 (25 %) among non-demented patients (p<0.001). Abnormal CSF biomarker levels 
were more prevalent in demented patients than in non-demented patients : 59/64 (92 %) vs 
41/65 (63%) were Aβ1-42+, and 43/64 (67 %) vs 36/65 (55%) were T-tau+.  
 
Delirium versus no delirium stratified on dementia status 
In stratified analyses a marked reduction in CSF Aβ1-42 was found in patients with delirium 
as compared with those without, while T-tau showed a mild increase and P-tau no significant 
difference (Table 2 and Figure 1). No CSF biomarker showed statistically significant 
differences for the demented stratum (Table 2 and Figure 1). CSF AβX-42, AβX-40, and 
AβX-38 concentrations were not associated with delirium in any of the strata (Table 2). 
Because the degree of cognitive impairment might have confounded the association despite 
the stratification procedure, we entered CSF biomarkers and biomarker ratios, age, gender, 
and IQCODE scores into logistic regression models with delirium status as the dependent 
variable. This analysis was limited to the dementia-free stratum, where the associations had 
been observed in bivariate analyses. CSF levels of Aβ1-42 and T-tau and the ratios of Aβ42 
to AβX-40, Tau and P-tau, remained significantly associated with delirium status in these 
analyses. CSF P-tau levels were not significantly associated with delirium in the adjusted 
model (Table 3). 
 
Combinations of amyloid and tau pathology 
 Patients were then divided into four groups according to the presence of amyloid pathology 
(Aβ1-42+ or Aβ1-42-) and/or tau pathology (P-tau+ or P-tau-). Seventy-three % of the 
patients in the “Aβ1-42+ and P-tau+” group developed delirium, 56 % of the “Aβ1-42+  and 
P-tau-” did so, and among patients with negative Aβ1-42, 13 % of the P-tau+ and 29 % of the 
P-tau- developed delirium (Figure 2a). Also for these analyses, statistically significant 
differences were seen only in the dementia-free stratum (Figure 2b and c). In that stratum, 56 
% of the patients with evidence of both amyloid and tau pathology developed delirium, while 
the three other groups had a delirium occurrence below 20 % (Figure 2b). In the stratum with 
dementia, around 85 % of the Aβ1-42+ patients developed delirium (Figure 2c).    
 
Comparison of hip fracture patients and cognitively normal older individuals 
CSF concentrations in hip fracture patients with delirium were 36 % of those in cognitively 
normal older individuals for Aβ1-42 and 127 % of those in cognitively normal older 
individuals for T-tau. The hip fracture patients without delirium were older, frailer, had more 
dementia and other comorbid disorders than the cognitively normal older individuals (Table 
1). CSF levels of Aβ1-42 and the ratios of Aβ42 to AβX-40, T-tau, and P-tau were 
significantly lower in hip fracture patients without delirium compared to cognitively normal 
older individuals (Table 1). There were, however, no differences in CSF T-tau and P-tau 
levels between these two groups (Table 1). 
 
DISCUSSION 
 
This is, to our knowledge, the first study to examine the relationship between preoperative 
CSF levels of Aβ42, T-tau and P-tau and delirium in both demented and non-demented 
patients. It is also the first study to show a convincing association between these biomarkers 
and delirium. We found lower CSF Aβ1-42 levels and also clearly lower ratios of Aβ42 to 
AβX-40, T-tau and P-tau, together with an increase in CSF T-tau levels in hip fracture 
patients who developed delirium compared to those who remained delirium free. 
 
In analyses stratified on dementia status, we found that CSF Aβ1-42, T-tau and all ratios were 
significantly associated with delirium in non-demented hip fracture patients, irrespective of 
age, gender and IQCODE score. This indicates that preclinical AD pathology increases the 
risk of delirium before the patient experiences a chronic cognitive impairment. It is well 
established that reduced CSF Aβ42 concentration reflects accumulation of aggregated Aβ in 
amyloid plaques in the brain,5,6 also in cognitively normal individuals,37 but there is very 
limited data on whether amyloid pathology in non-demented elderly has any clinical 
consequences. An important finding is therefore that non-demented elderly with clinically 
silent amyloid pathology were found to develop symptoms (i.e. delirium) when exposed to 
physical stress. Amyloid pathology has been associated with dysfunction in brain networks in 
cognitively normal individuals,38-42 and a breakdown of network connectivity in the brain has 
been suggested to be the neurobiological substrate of delirium.43 It is likely that axonal 
degeneration and tangle pathology reflected by CSF T-tau and P-tau also have detrimental 
effects on brain network connectivity.42 We found that non-demented patients with positive 
Aβ1-42 and P-tau were more likely to develop delirium than patients with an abnormality in 
only one of these two biomarkers, thus the vulnerability to delirium seems to increase with an 
increasing degree of neuropathology. [Hela stycket ovan är jättebra !!]   
 Although delirium is an independent risk factor for incident dementia,3 our findings raise the 
question of whether delirium simply unmasks a preclinical dementia. Also hip fracture 
patients without delirium had more pathological CSF biomarkers than the cognitively normal 
older individuals. This indicates that hip fracture patients constitute a frail population with a 
high prevalence of preclinical dementia even in patients who do not develop delirium.  
 
Cavallari and colleagues did not find an association between any MRI measures of white-
matter damage, global brain, and hippocampal volume and the incidence of delirium in a 
population of non-demented patients.44 A possible explanation could be that most non-
demented patients have insufficient structural brain pathology at a macroscopic level to be 
detected by MRI. CSF biomarkers may have a greater potential for detecting early brain 
pathology relevant for delirium.  
 
We found no significant associations between the CSF biomarkers and delirium in hip 
fracture patients with dementia. Patients with dementia have more extensive brain pathology, 
and in our study almost all demented patients had abnormal CSF biomarkers and developed 
delirium. The abnormalities in biomarkers have likely reached a plateau in dementia,11 thus 
the differences in biomarker levels between demented patients are likely to be small. 
 
Witlox and colleagues performed a prospective cohort study in elderly hip fracture patients 
similar to our study.13 However, they excluded patients with a dementia diagnosis. They 
found no association between biomarkers and delirium. The biomarker levels in their study, 
both in patients with and without delirium, were much closer to the normal values than we 
found. This might indicate that AD brain pathology was less prevalent in their study 
population. Xie and colleagues found CSF levels of Aβ42 and T-tau more similar to our 
findings.14 Like Witlox and colleagues, they did not find an association between preoperative 
CSF biomarker levels and postoperative delirium in a population ≥ 63 years old having 
elective total hip or knee replacement. However, when they divided the participants into 
quartiles according to Aβ40/T-tau and Aβ42/Tau ratios, they found a higher delirium 
incidence in the lowest quartile.  
 
Strengths of our study include the daily and bedside assessment of delirium with validated 
instruments and the inclusion of patients both with and without dementia. A larger number of 
patients included than in other delirium biomarker studies made subgroup analyses on 
dementia and time of delirium debut possible. CSF was analyzed in a laboratory with an 
extensive experience on Aβ42, T-tau and P-tau analyzes in CSF.  
 
Some limitations deserve a comment. The study might have been underpowered to detect 
biomarker differences by delirium status in the demented stratum, because demented patients 
had a high occurrence of delirium and a high prevalence of abnormal CSF biomarkers. 
Dementia diagnoses based on a cognitive assessment before the patients became hospitalized 
would be better than our retrospective dementia diagnoses. However, since hip fracture 
patients are acutely admitted to the hospital, this was not feasible. We also believe that our 
consensus diagnosis of dementia is more accurate than merely IQCODE cut-offs. The 
dementia diagnosis is, however, not etiological, thus even though a high proportion of the 
patients with dementia likely have AD dementia, they may also have other dementias. 
 Larger studies of different populations are needed to more firmly assess the potential 
association between Aβ42, T-tau and P-tau and delirium.  
 
CONCLUSION 
 
We demonstrate a marked reduction in CSF Aβ42, indicating β-amylodosis, together with a 
mild increase in T-tau, indicating neurodegeneration, in cognitively normal elderly hip 
fracture patients developing delirium. These findings indicate that preclinical brain 
amyloidosis have clinical consequences and suggest that these patients have preclinical AD. 
The CSF biomarkers may be analyzed preoperatively in hip fracture patients, thereby 
allowing an increased focus on delirium prevention in elderly patients with abnormal 
biomarkers. 
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FIGURE LEGENDS 
Figure 1. CSF Ab1-42, AbX-42/X-40 ratio, T-tau and Ab1-42/T-tau ratio in non-demented 
patients with and without delirium. 
Footnotes: Dementia status was based upon consensus between two experienced clinicians. There were 16 
patients with delirium and 49 without. P-values were calculated using Mann-Whitney U-tests.  
 
Figure 2. Delirium occurrence according to combinations of amyloid and tau pathology. 
Explanatory legends: Percent of patients who developed delirium during the hospital stay according to 
grouping by positive and negative Aβ-42 and P-tau values. Subjects were classified as Aβ1-42+ (< 530 ng/L) or 
Aβ1-42- (≥ 530 ng/L), and P-tau+ (≥ 60 ng/L) or P-tau- (< 60 ng/L). P-values were calculated using Chi-Square 
and Fisher’s Exact Tests. a) all hip fracture patients, b) hip fracture patients without dementia c) hip fracture 
patients with dementia.  
 
eFigure1. Selection of CSF samples 
Explanatory legends: Cognitively normal older individual was defined as maximum one abnormal score on 
cognitive tests.  
  
TABLES 
Table 1. Baseline Characteristics. 
Hip Fracture Patients (n=129)  Cognitively normal older 
individuals  
(n=121) 
Without 
Delirium  
(n=59) 
With Delirium  
(n=70) 
P 
valuea 
P 
valueb 
Age, median (range)  72 (64 to 93) 83 (60 to 94) 85 (68 to 101) .02 <.001 
Male, n (%) 59 (49) 13 (22) 21 (30) .31c .001c 
IQCODE, median 
(range)e 
3.00 (2.69 to 3.56) 3.19 (3.00 to 
5.00) 
4.53 (3.00 to 
5.00) 
<.001 <.001 
Dementia, n (%)f 0 (0) 10 (17) 54 (77) <.001c - 
Nursing home, n (%) - 9 (15) 34 (49) <.001c - 
APACHE II, median 
(range)g 
- 8 (5 to 14) 9 (6 to 21) .004 - 
Barthel ADL, median 
(range) 
- 19 (4 to 20) 15 (3 to 20) <.001 - 
ASA scoreh 
  I, n (%) 
  II, n (%) 
  III, n (%) 
  IV, n (%) 
-  
1 (2) 
31 (54) 
25 (44) 
0 (0) 
 
0 (0) 
19 (28) 
47 (69) 
2 (3) 
- 
 
- 
Stroke or TIA, n (%) - 9 (15) 13 (19) .62c - 
Diabetes mellitus, n 
(%) 
15 (12) 8 (14) 11 (16) .73c .83c 
Ischemic heart disease, 
n (%) 
16 (13) 13 (22) 18 (26) .63c .13c 
Aβ1-42, ng/L, median 
(range) 
737 (275 to 1175) 461 (125 to 
1086) 
267 (125 to 
713) 
< .001 <.001 
Aβ1-42+ (< 530 ng/L), 
n (%) 
32 (26) 36 (61) 64 (91) <.001c <.001c 
T-Tau, ng/L, median 
(range) 
347 (114 to 826) 360 (133 to 
1034) 
439 (91 to 
1380) 
.006 .92 
T-tau+ (> 350 ng/L), n 
(%) 
59 (49) 31 (53) 48 (69) .06c .63c 
P-tau, ng/L, median 
(range) 
59 (25 to 115) 55 (18 to 118) 60 (20 to 201) .25 .35 
P-tau+ (≥ 60 ng/L), n 
(%) 
55 (46) 25 (42) 35 (50) .39c .70c 
AβX-42, ng/L, median 
(range)i 
417 (88 to 1106) 225 (25 to 
1029) 
123.5 (38 to 
612) 
<0.001 <0.001 
AβX-40, ng/L, median 
(range)i 
4873 (2220 to 10187) 3488 (779 to 
8535) 
2916 (1130 to 
6490) 
0.003 <0.001 
AβX-38, ng/L, median 
(range)i 
2054 (828 to 4994) 1548 (260 to 
3867) 
1120 (353 to 
3732) 
0.004 <0.001 
AβX-42/X-40, median 
(range)i 
0.09 (0.03 to 0.13) 0.07 (0.02 to 
0.14) 
0.04 (0.02 to 
0.14) 
<.001 .001 
Aβ1-42/T-tau, median 
(range) 
2.07 (0.44 to 4.30) 1.38 (0.15 to 
5.73) 
0.56 (0.09 to 
2.45) 
<.001 <.001 
Aβ1-42/P-tau, median 
(range) 
13.09 (3.40 to 24.72) 8.96 (1.37 to 
31.60) 
4.40 (0.86 to 
14.71) 
<.001 <.001 
Abbreviations: IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly. APACHE II = Acute 
Physiology and Chronic Health Evaluation II. Barthel ADL = Barthel Index of Activities of Daily Living. ASA-
score = Score of The American Society of Anaesthesiologists’ classification of Physical Health. TIA = Transient 
Ischemic Attack. P-values were calculated using Mann-Whitney U-test if not otherwise specified. Aβ 1-42 was 
measured using INNOTEST enzyme-linked immunosorbent assays (ELISA) if not otherwise specified.  
a Comparing hip fracture patients with and without delirium 
b Comparing cognitively normal older individuals with hip fracture patients without delirium 
c Chi-square test 
d Fischer´s exact test 
e Missing in two patients with hip fracture without delirium and in two cognitively normal older individuals 
f Based upon consensus in an expert panel 
g APACHE II score without hematocrit and blood gas values 
h Missing in two patients with delirium and two patients without delirium 
i AβX-42, AβX-40 and AβX-38 were measured with Aβ Triplex Assay  
 
Table 2. CSF markers in relation to delirium and dementia status. 
No dementia  
Without Delirium  
(n=49) 
With Delirium 
(n=16) 
P value 
Aβ1-42, ng/L 489 (133 to 1086) 310 (125 to 633) .006 
T-Tau, ng/L 351 (132 to 808) 505 (187 to 1266) .02 
P-tau, ng/L 54 (18 to 118) 72 (25 to 154) .06 
AβX-42, ng/L 230 (57 to 1029) 142.5 (90 to 612) 0.085 
AβX-40, ng/L 3488 (967 to 8535) 3281.5 (1598 to 6490) 0.69 
AβX-38, ng/L 1548 (276 to 3867) 1434 (477 to 3732) 0.67 
AβX-42/X-40 .08 (.02 to .14) .04 (.03 to .14) .004 
Aβ1-42/T-tau 1.59 (.16 to 5.73) .52 (.25 to 2.45) <.001 
Aβ1-42/P-tau 9.96 (1.37 to 31.60) 3.89 (1.82 to 14.71) .001 
 Dementia P value 
 Without Delirium With Delirium  
(n=10) (n=54) 
Aβ1-42, ng/L 317.5 (125 to 675) 257.5 (125 to 713) .43 
T-Tau, ng/L 441 (114 to 1034) 410 (91 to 1380) .67 
P-tau, ng/L 61 (19 to 109) 56 (20 to 201) .94 
AβX-42, ng/L 146.5 (25 to 447) 116.5 (38 to 472) 0.24 
AβX-40, ng/L 3414 (779 to 5590) 2466 (1130 to 6210) 0.20 
AβX-38, ng/L 1356.0 (260 to 2241) 987 (353 to 3274) 0.24 
AβX-42/X-40 .05 (0.02 to 0.08) .04 (0.02 to 0.11) .24 
Aβ1-42/T-tau .96 (0.15 to 1.41) .61 (0.09 to 2.39) .17 
Aβ1-42/P-tau 7.21 (1.42 to 10.68) 4.61 (0.86 to 14.34) .24 
Footnotes: Values are median (range). P-values were calculated using Mann-Whitney U-test. 
 
Table 3. Logistic regression analyzes controlling for age, gender and cognition. 
Explanatory legend: Logistic regression analyzes controlling for potential confounders of the association 
between delirium and biomarkers in patients without dementia 
Unadjusted Adjusted by age, gender and IQCODE score  
OR 95 % CI OR  95 % CI 
Aβ1-42, ng/L .995 .992 to .999 .993 .989 to .998 
T-tau, ng/L 1.004 1.001 to 1.007 1.003 1.000 to 1.006 
P-tau, ng/L 1.023 1.002 to 1.045 1.019 .987 to 1.042 
AβX-42/X-40 ratio x10 .058 .005 to .615 .043 .002 to .863 
Aβ1-42/T-tau ratio .18 .06 to .56 .16 .04 to .61 
Aβ1-42/P-tau ratio .76 .63 to .92 .75 .60 to .93 
Footnotes: The table displays the odds ratio of developing delirium per unit change in the biomarkers and ratios. 
AbX-42/X-40 ratio is multiplied with 10 in order to get a more meaningful OR. Abbreviations: OR = Odds 
Ratio. CI = Confidence Interval. IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly. 
Removal of outliers, defined as standard residuals > ± 3 or Cook´s distance > 1, did not change the odds ratios 
or significance of the biomarkers considerably, and outliers were therefore kept in the model.  
 
